You are here

  • Home
  • Archive
  • Volume 2, Issue Suppl 3
  • A Phase I, first-in-human, open label, dose escalation study of MGD007, a humanized gpA33 × CD3 dual-affinity re-targeting (DART®) protein in patients with relapsed/refractory metastatic colorectal carcinoma

Article metrics

Article menu

Download PDFPDF

Poster Presentation
A Phase I, first-in-human, open label, dose escalation study of MGD007, a humanized gpA33 × CD3 dual-affinity re-targeting (DART®) protein in patients with relapsed/refractory metastatic colorectal carcinoma
Free

 

Online download statistics by month:

Online download statistics by month: December 2019 to September 2024

AbstractFullPdf
Dec 2019010
Jan 2020041
Feb 2020051
Apr 2020010
May 2020051
Jun 2020080
Jul 2020050
Aug 2020022
Sep 20200111
Oct 2020010
Nov 2020031
Dec 2020010
Jan 2021030
Feb 2021001
Mar 2021020
Apr 2021052
Jun 2021031
Jul 2021030
Aug 2021030
Sep 2021040
Oct 2021093
Nov 2021084
Dec 2021094
Jan 2022051
Feb 2022041
Mar 2022042
Apr 20220103
May 20220102
Jun 2022074
Jul 20220143
Aug 2022063
Sep 2022062
Oct 20220103
Nov 20220313
Dec 20220161
Jan 20230140
Feb 2023051
Mar 2023043
Apr 2023011
May 20230122
Jun 20230145
Jul 2023041
Aug 2023083
Sep 2023071
Oct 20230131
Nov 2023061
Dec 2023051
Jan 20240254
Feb 20240141
Mar 20240951
Apr 20240614
May 2024093
Jun 2024060
Jul 2024071
Aug 2024090
Sep 2024054
Total0402148